All In Biotech

Drug Trial Radar · NCT02248753

Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department

Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department (RACE 7 ACWAS-trial)

Last checked: Nov 19, 2026Latest source record: Jan 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 437 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

437

Actual

Start

Oct 2014

Primary completion

Nov 2018

Study completion Dec 2019

Sponsor

Lead sponsor
Maastricht University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
First posted
Sep 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A symptomatic episode of the heart rhythm disorder 'atrial fibrillation' (AF) is a frequent reason for visits to the emergency department. Currently, in the majority of cases, immediate (electrical or pharmacological) cardioversion is chosen, while atrial fibrillation terminates spontaneously in 70% of the cases within 24 hours. A wait-and-see approach with rate-control medication only, and when needed cardioversion within 48 hours of onset of symptoms, could be effective, safe and more cost-effective than current standard of care and could lead to a higher quality of life.

Conditions

  • Atrial Fibrillation

Interventions

  • Pharmacological cardioversion - FlecainideDrug

  • Electrical cardioversionProcedure

  • MetoprololDrug

  • VerapamilDrug

  • DigoxinDrug

  • Pharmacological cardioversion - AmiodaroneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 12-lead ECGTime frame: 4 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • VU University Medical Center

    Amsterdam, Netherlands

  • Amphia Hospital

    Breda, Netherlands

  • Catharina Ziekenhuis

    Eindhoven, Netherlands

  • Medisch Spectrum Twente

    Enschede, Netherlands

  • University Medical Center Groningen

    Groningen, Netherlands

  • Zuyderland Medical Center

    Heerlen, Netherlands

  • Alrijne Hospital

    Leiderdorp, Netherlands

  • Maastricht University Medical Center

    Maastricht, Netherlands

  • St. Antonius Hospital

    Nieuwegein, Netherlands

  • Franciscus Gasthuis

    Rotterdam, Netherlands

  • Antonius Ziekenhuis

    Sneek, Netherlands

  • HagaZiekenhuis

    The Hague, Netherlands

  • St. Elisabeth - TweeSteden Hospital

    Tilburg, Netherlands

  • Diakonessenhuis

    Utrecht, Netherlands

  • VieCuri Medical Center

    Venlo, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.